Acadia Pharmaceuticals (ACAD) PT Raised to $50 at Jefferies on Higher Nuplazid Sales Estimates
Tweet Send to a Friend
Jefferies analyst Thomas Wei reiterated a Buy rating and boosted his price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $50.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
